Download PDF
Klinische Neurophysiologie 2001; 32(4): 213-217
DOI: 10.1055/s-2001-18960
Originalia
© Georg Thieme Verlag Stuttgart · New York

Perspektiven der Botulinumtoxintherapie der Dystonien

Perspectives of Botulinum Toxin Treatment of DystoniasD.  Dressler1 , R.  Benecke1
  • 1Klinik für Neurologie, Universität Rostock
Further Information

Publication History

Publication Date:
11 December 2001 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die therapeutische Anwendung von Botulinumtoxin (BT) hat sich seit ihrer Einführung in die deutsche Neurologie vor zwölf Jahren als erfolgreichstes Verfahren zur Behandlung von Dystonien und anderen Muskelüberaktivitätssyndromen etabliert. In der vorliegenden Übersicht werden immunologische Aspekte der BT-Therapie, Konversionsfaktoren zum Vergleich verschiedener BT-Päparationen, Anwendungsmöglichkeiten der Elektromyographie bei der Planung und Durchführung der BT-Therapie, Entwicklungen neuer BT-Präparationen und Versorgungsstrukturen der BT-Therapie dargestellt.

Abstract

Therapeutic use of botulinum toxin (BT) is now established as the most effective treatment for dystonia and other muscle hyperactivity syndromes after it was introduced to German neurology 12 years ago. In this review, immunological aspects of BT therapy, conversion factors for comparison of different BT preparations, use of electromyography for planning and application of BT therapy, development of new BT preparations and health care system structures for providing BT therapy are presented.

Key words

Botulinum toxin - Therapy - Dystonia - Immunology - Conversion factors - Electromyography - Type A - Type B - Health care system

Literatur

  • 1 Dressler D, Benecke R, Conrad B. Botulinum-Toxin in der Therapie kraniozervikaler Dystonien.  Nervenarzt. 1989;  60 386-393
    PubMedGoogle Scholar
  • 2 Dressler D. Botulinum-Toxin-Therapie. Stuttgart; Thieme Verlag 1995
    Google Scholar
  • 3 Dressler D. Botulinum Toxin Therapy. Stuttgart, New York; Thieme Verlag 2000
    Google Scholar
  • 4 Jankovic J, Hallett M. Therapy with Botulinum Toxin. New York, Basel, Hongkong; Marcel Dekker 1994
    Google Scholar
  • 5 Moore P. Handbook of Botulinum Toxin Treatment. Oxford; Blackwell Science 1995
    Google Scholar
  • 6 Laskawi R, Roggenkämper P. Botulinum-Toxin-Therapie im Kopf-Hals-Bereich. München; Urban & Vogel 1999
    Google Scholar
  • 7 Biglan A W, Gonnering R, Lockhart L B, Rabin B, Fuerste F H. Absence of antibody production in patients treated with botulinum A toxin.  Am J Ophthalmol. 1986;  101 232-235
    PubMedGoogle Scholar
  • 8 Gonnering R S. Negative antibody response to long-term treatment of facial spasm with botulinum toxin.  Am J Ophthalmol. 1988;  105 313-315
    PubMedGoogle Scholar
  • 9 Wittstock M, Benecke R, Bigalke H, Dressler D. Quantitative antibody status of patients with continued sensitivity to long-term botulinum toxin therapy.  Neurology. 2001;  56 (Suppl 3) A347
    PubMedGoogle Scholar
  • 10 Kessler K R, Skutta M, Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group.  J Neurol. 1999;  246 265-274
    CrossrefPubMedGoogle Scholar
  • 11 Herrmann J, Mall V, Bigalke H, Geth K, Korinthenberg R, Heinen F. Secondary non-response due to development of neutralising antibodies to botulinum toxin A during treatment of children with cerebral palsy.  Neuropediatrics. 2000;  31 333-334
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Pearce L B, Borodic G E, First E R, MacCallum R D. Measurement of botulinum toxin activity: evaluation of the lethality assay.  Toxicol Appl Pharmacol. 1994;  128 69-77
    CrossrefPubMedGoogle Scholar
  • 13 Göschel H, Wohlfahrt K, Frevert J, Dengler R, Bigalke H. Botulinum A toxin: Neutralizing and nonneutralizing antibodies - therapeutic consequences.  Exp Neurol. 1997;  147 96-102
    CrossrefPubMedGoogle Scholar
  • 14 Palace J, Nairne A, Hyman N, Doherty T V, Vincent A. A radioimmuno-precipitation assay for antibodies to botulinum A.  Neurology. 1998;  50 1463-1466
    PubMedGoogle Scholar
  • 15 Dressler D, Dirnberger G, Bhatia K, Quinn N P, Irmer A, Bigalke H, Marsden C D. Botulinum toxin antibody testing: comparison between the mouse diaphragm bioassay and the mouse lethality bioassay.  Mov Disord. 2000;  15 973-976
    CrossrefPubMedGoogle Scholar
  • 16 Dressler D, Rothwell J C, Bigalke H. The sternocleidomastoid test: an in-vivo assay to investigate botulinum toxin antibody formation in man.  J Neurol. 2000;  247 630-632
    PubMedGoogle Scholar
  • 17 Kessler K R, Benecke R. The EBD test - a clinical test for the detection of antibodies to botulinum toxin type A.  Mov Disord. 1997;  12 95-99
    CrossrefPubMedGoogle Scholar
  • 18 Dressler D. Botulinum toxin therapy failure: causes, evaluation procedures and management strategies.  Eur J Neurol. 1997;  4 (suppl 2) S67-S70
    PubMedGoogle Scholar
  • 19 Dressler D. Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 2001 (in press)
    Google Scholar
  • 20 Dressler D. Managing Patients with Botulinum Toxin Antibodies. In: Brin MF, Jankovic J, Hallett M (eds) Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia; Lippincott Williams & Wilkins 2001 (in press)
    Google Scholar
  • 21 Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis.  Mov Disord. 1994;  9 213-217
    CrossrefPubMedGoogle Scholar
  • 22 Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections.  Neurology. 1995;  45 1743-1746
    PubMedGoogle Scholar
  • 23 Dressler D, Dirnberger G. Risk factors for therapy failure.  Mov Disord. 2000;  15 (suppl 2) 51
    PubMedGoogle Scholar
  • 24 Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm.  J Neurol. 2000;  247 809-810
    PubMedGoogle Scholar
  • 25 Poewe W, Wissel J. Experience with botulinum toxin in cervical dystonia. In: Jankovic J, Hallett M (eds) Therapy with Botulinum Toxin. New York, Basel, Hongkong; Marcel Dekker 1994: 267-278
    Google Scholar
  • 26 First E R, Pearce L B, Borodic G E. Dose standardisation of botulinum toxin.  Lancet. 1994;  343 1035
    PubMedGoogle Scholar
  • 27 van den Bergh P, Lison D. Dose standardisation of BTX. 3rd International Dystonia Symposium, October 9 - 11, 1996,. Miami, Florida; Chicago, Illinois; Affiliated National Dystonia Associations 1996: p30
    Google Scholar
  • 28 Hambleton P, Pickett A M. Potency equivalence of botulinum toxin preparations.  J Roy Soc Med. 1994;  87 719
    PubMedGoogle Scholar
  • 29 Dressler D, Rothwell J C. Electromyographic quantification of the paralysing effect of botulinum toxin.  Eur Neurol. 2000;  43 13-16
    CrossrefPubMedGoogle Scholar
  • 30 Sloop R R, Escutin R O, Matus J A, Cole B A, Peterson G W. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A.  Neurology. 1996;  46 1382-1386
    PubMedGoogle Scholar
  • 31 Sloop R R, Cole B A, Escutin R O. Human response to botulinum toxin injection: type B compared with type A.  Neurology. 1997;  49 189-194
    PubMedGoogle Scholar
  • 32 Wohlfahrt K, Göschel H, Frevert J, Dengler R, Bigalke H. Botulinum A toxins: units versus units.  Naunyn Schmiedeberg's Arch Pharmacol. 1997;  355 335-340
    PubMedGoogle Scholar
  • 33 Dressler D, Rothwell J C, Marsden C D. Comparing biological potencies of Botox® and Dysport® with a mouse diaphragm model may mislead.  J Neurol. 1998;  245 332
    PubMedGoogle Scholar
  • 34 Ostergaard L, Fuglsang-Frederiksen A, Sjo O, Werdelin L, Winkel H. Quantitative EMG in cervical dystonia.  Electromyogr Clin Neurophysiol. 1996;  36 179-185
    PubMedGoogle Scholar
  • 35 Van Gerpen J A, Matsumoto J Y, Ahlskog J E, Maraganore D M, McManis P G. Utility of an EMG mapping study in treating cervical dystonia.  Muscle Nerve. 2000;  23 1752-1756
    CrossrefPubMedGoogle Scholar
  • 36 Dressler D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy.  Eur J Neurol. 2000;  7 713-718
    CrossrefPubMedGoogle Scholar
  • 37 Comella C L, Buchman A S, Tanner C M, Brown-Toms N C, Goetz C G. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance.  Neurology. 1992;  42 878-882
    CrossrefPubMedGoogle Scholar
  • 38 Blitzer A, Brin M F, Stewart C F. Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12-year experience in more than 900 patients.  Laryngoscope. 1998;  108 1435-1441
    CrossrefPubMedGoogle Scholar
  • 39 Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia.  Can J Neurol Sci. 1996;  23 194-197
    PubMedGoogle Scholar
  • 40 Brashear A, Lew M F, Dykstra D D, Comella C L, Factor S A, Rodnitzky R L, Trosch R, Singer C, Brin M F, Murray J J, Wallace J D, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.  Neurology. 1999;  53 1439-1446
    CrossrefPubMedGoogle Scholar
  • 41 Brin M F, Lew M F, Adler C H, Comella C L, Factor S A, Jankovic J, O'Brien C, Murray J J, Wallace J D, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.  Neurology. 1999;  53 1431-1438
    CrossrefPubMedGoogle Scholar
  • 42 Dressler D, Benecke B. Autonomic side effects of botulinum toxin type B therapy. Mov Disord 2001 (in press)
    Google Scholar

Dr. Dirk Dressler

Klinik für Neurologie · Universität Rostock

Gehlsheimer Straße 20

18147 Rostock

Email: dirk.dressler@med.uni-rostock.de

      >